Rebecca Taub Sells 647 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Rebecca Taub sold 647 shares of the stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $492.42, for a total value of $318,595.74. Following the completion of the transaction, the director directly owned 452,704 shares in the company, valued at $222,920,503.68. The trade was a 0.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Rebecca Taub also recently made the following trade(s):

• On Tuesday, January 20th, Rebecca Taub sold 2,238 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $490.77, for a total value of $1,098,343.26.
• On Friday, January 9th, Rebecca Taub sold 18,410 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $522.40, for a total transaction of $9,617,384.00.
• On Friday, January 9th, Rebecca Taub sold 240 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $550.33, for a total transaction of $132,079.20.
• On Wednesday, December 10th, Rebecca Taub sold 18,650 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $552.15, for a total transaction of $10,297,597.50.

Madrigal Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ MDGL opened at $500.39 on Wednesday. Madrigal Pharmaceuticals, Inc. has a twelve month low of $265.00 and a twelve month high of $615.00. The stock has a market cap of $11.36 billion, a price-to-earnings ratio of -38.46, a P/E/G ratio of 4.84 and a beta of -1.00. The company has a quick ratio of 3.26, a current ratio of 3.44 and a debt-to-equity ratio of 0.54. The company’s fifty day moving average is $556.89 and its 200-day moving average is $462.94.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) EPS for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative return on equity of 41.50% and a negative net margin of 39.04%. Equities research analysts predict that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on MDGL shares. Wolfe Research set a $579.00 target price on Madrigal Pharmaceuticals in a research note on Tuesday, January 6th. HC Wainwright increased their price objective on shares of Madrigal Pharmaceuticals from $568.00 to $620.00 and gave the stock a “buy” rating in a research report on Friday, November 21st. Zacks Research cut shares of Madrigal Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, January 12th. B. Riley upped their target price on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Bank of America raised Madrigal Pharmaceuticals from an “underperform” rating to a “neutral” rating and lifted their price target for the company from $266.00 to $445.00 in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $654.73.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AlphaQuest LLC boosted its stake in shares of Madrigal Pharmaceuticals by 412.5% during the 2nd quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 66 shares during the last quarter. Flagship Harbor Advisors LLC bought a new stake in Madrigal Pharmaceuticals during the fourth quarter worth about $29,000. Mather Group LLC. acquired a new position in Madrigal Pharmaceuticals during the third quarter valued at approximately $33,000. Global Retirement Partners LLC grew its stake in Madrigal Pharmaceuticals by 221.7% in the third quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 51 shares in the last quarter. Finally, First Horizon Corp acquired a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter worth approximately $34,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.